Skip to main content
. 2015 Dec 4;10(12):e0143830. doi: 10.1371/journal.pone.0143830

Fig 1. Postulated effects of everolimus and lovastatin on signaling pathways: lovastatin has been described to inhibit EGFR, AKT and ERK signaling, but has been found to increase mTORC1/p70S6K signaling; everolimus is known to inhibit mTORC1, but to increase AKT signaling.

Fig 1